BioNTech shares (BNTX) are down 16% YTD heading into this morning’s earnings, with the Street expecting a larger loss for the second quarter of 2026 when results are released before market open this morning. The consensus estimate sits at a loss of US$2.08 per share, wider than the US$1.60 loss recorded in the same quarter last year.
Revenue expectations reflect continued contraction in the COVID-19 vaccine business. Analysts forecast US$155.7 million in Q2 revenue, down 40% Y/Y.
What To Watch
The most immediate catalyst heading into the print is the recent approval of BioNTech and Pfizer’s XFG-adapted COVID-19 vaccine by the European Commission. The authorisation was granted last week (29 July), following a recommendation from the European Medicines Agency’s Emergency Task Force to update vaccines for the 2026-2027 respiratory season.
The vaccine targets the XFG variant of the JN.1 lineage and is authorised for use in individuals aged six months and older across all 27 EU member states, plus Iceland, Liechtenstein, and Norway. BioNTech and Pfizer stated they have already begun manufacturing the updated vaccine at risk to ensure supply readiness ahead of the northern hemisphere respiratory season.
While the approval is a positive development, it is unlikely to move the needle materially on Q2 results. Manufacturing and distribution timelines mean revenue contribution from the updated vaccine will only appear in later quarters, assuming demand recovers during the upcoming flu and COVID season.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Beyond the vaccine business, investors will be listening for updates on BioNTech’s oncology pipeline. Recent coverage noted the company is pivoting toward cancer therapies as its core growth strategy, with oncology representing a US$500 billion annual market globally. Any commentary on clinical trial progress, regulatory timelines, or partnerships in this space could influence sentiment after the print.
Guidance for the second half of 2026 will also matter. If management signals stabilisation in vaccine revenue or highlights operational efficiencies, the market may view the widening loss as a transitional period rather than a structural problem. Conversely, further deterioration in COVID-19 revenue without clear oncology milestones could weigh on the stock.
Options markets are pricing a ~8.5% move following the print, which could see a bullish report see a recapture of $100, or a breakdown towards the 52 week low of $79.52.
